These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 29300371)

  • 1. Which Lynch syndrome screening programs could be implemented in the "real world"? A systematic review of economic evaluations.
    Di Marco M; DAndrea E; Panic N; Baccolini V; Migliara G; Marzuillo C; De Vito C; Pastorino R; Boccia S; Villari P
    Genet Med; 2018 Oct; 20(10):1131-1144. PubMed ID: 29300371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Costs and outcomes of Lynch syndrome screening in the Australian colorectal cancer population.
    Cenin DR; Naber SK; Lansdorp-Vogelaar I; Jenkins MA; Buchanan DD; Preen DB; Ee HC; O'Leary P
    J Gastroenterol Hepatol; 2018 Oct; 33(10):1737-1744. PubMed ID: 29645364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation.
    Snowsill T; Coelho H; Huxley N; Jones-Hughes T; Briscoe S; Frayling IM; Hyde C
    Health Technol Assess; 2017 Sep; 21(51):1-238. PubMed ID: 28895526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of routine screening for Lynch syndrome in colorectal cancer patients up to 70 years of age.
    Leenen CH; Goverde A; de Bekker-Grob EW; Wagner A; van Lier MG; Spaander MC; Bruno MJ; Tops CM; van den Ouweland AM; Dubbink HJ; Kuipers EJ; Dinjens WN; van Leerdam ME; Steyerberg EW
    Genet Med; 2016 Oct; 18(10):966-73. PubMed ID: 26938782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis.
    Ladabaum U; Wang G; Terdiman J; Blanco A; Kuppermann M; Boland CR; Ford J; Elkin E; Phillips KA
    Ann Intern Med; 2011 Jul; 155(2):69-79. PubMed ID: 21768580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of genetic diagnostic strategies for Lynch syndrome in Italy.
    Pastorino R; Basile M; Tognetto A; Di Marco M; Grossi A; Lucci-Cordisco E; Scaldaferri F; De Censi A; Federici A; Villari P; Genuardi M; Ricciardi W; Boccia S
    PLoS One; 2020; 15(7):e0235038. PubMed ID: 32609729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome.
    Snowsill T; Huxley N; Hoyle M; Jones-Hughes T; Coelho H; Cooper C; Frayling I; Hyde C
    Health Technol Assess; 2014 Sep; 18(58):1-406. PubMed ID: 25244061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness Analysis of Different Genetic Testing Strategies for Lynch Syndrome in Taiwan.
    Chen YE; Kao SS; Chung RH
    PLoS One; 2016; 11(8):e0160599. PubMed ID: 27482709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Universal Versus Targeted Screening for Lynch Syndrome: Comparing Ascertainment and Costs Based on Clinical Experience.
    Erten MZ; Fernandez LP; Ng HK; McKinnon WC; Heald B; Koliba CJ; Greenblatt MS
    Dig Dis Sci; 2016 Oct; 61(10):2887-2895. PubMed ID: 27384051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer.
    Hampel H; Pearlman R; Beightol M; Zhao W; Jones D; Frankel WL; Goodfellow PJ; Yilmaz A; Miller K; Bacher J; Jacobson A; Paskett E; Shields PG; Goldberg RM; de la Chapelle A; Shirts BH; Pritchard CC;
    JAMA Oncol; 2018 Jun; 4(6):806-813. PubMed ID: 29596542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness of screening strategies for Lynch syndrome.
    Barzi A; Sadeghi S; Kattan MW; Meropol NJ
    J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25794514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The predicted impact and cost-effectiveness of systematic testing of people with incident colorectal cancer for Lynch syndrome.
    Kang YJ; Killen J; Caruana M; Simms K; Taylor N; Frayling IM; Snowsill T; Huxley N; Coupe VM; Hughes S; Freeman V; Boussioutas A; Trainer AH; Ward RL; Mitchell G; Macrae FA; Canfell K
    Med J Aust; 2020 Feb; 212(2):72-81. PubMed ID: 31595523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for Lynch syndrome and referral to clinical genetics by selective mismatch repair protein immunohistochemistry testing: an audit and cost analysis.
    Colling R; Church DN; Carmichael J; Murphy L; East J; Risby P; Kerr R; Chetty R; Wang LM
    J Clin Pathol; 2015 Dec; 68(12):1036-9. PubMed ID: 26201544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fourfold increased detection of Lynch syndrome by raising age limit for tumour genetic testing from 50 to 70 years is cost-effective.
    Sie AS; Mensenkamp AR; Adang EMM; Ligtenberg MJL; Hoogerbrugge N
    Ann Oncol; 2014 Oct; 25(10):2001-2007. PubMed ID: 25081898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Swiss cost-effectiveness analysis of universal screening for Lynch syndrome of patients with colorectal cancer followed by cascade genetic testing of relatives.
    Salikhanov I; Heinimann K; Chappuis P; Buerki N; Graffeo R; Heinzelmann V; Rabaglio M; Taborelli M; Wieser S; Katapodi MC
    J Med Genet; 2022 Sep; 59(9):924-930. PubMed ID: 34782441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the impact of universal Lynch syndrome screening in a publicly funded healthcare system.
    Lee PWC; Bedard AC; Samimi S; Beard VK; Hong Q; Bedard JEJ; Gilks B; Schaeffer DF; Wolber R; Kwon JS; Lim HJ; Sun S; Schrader KA
    Cancer Med; 2020 Sep; 9(18):6507-6514. PubMed ID: 32700475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Age-dependent performance of BRAF mutation testing in Lynch syndrome diagnostics.
    Bläker H; Haupt S; Morak M; Holinski-Feder E; Arnold A; Horst D; Sieber-Frank J; Seidler F; von Winterfeld M; Alwers E; Chang-Claude J; Brenner H; Roth W; Engel C; Löffler M; Möslein G; Schackert HK; Weitz J; Perne C; Aretz S; Hüneburg R; Schmiegel W; Vangala D; Rahner N; Steinke-Lange V; Heuveline V; von Knebel Doeberitz M; Ahadova A; Hoffmeister M; Kloor M;
    Int J Cancer; 2020 Nov; 147(10):2801-2810. PubMed ID: 32875553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lynch syndrome screening in colorectal cancer: results of a prospective 2-year regional programme validating the NICE diagnostics guidance pathway throughout a 5.2-million population.
    West NP; Gallop N; Kaye D; Glover A; Young C; Hutchins GGA; Brockmoeller SF; Westwood AC; Rossington H; Quirke P;
    Histopathology; 2021 Nov; 79(5):690-699. PubMed ID: 33872400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population-based screening for Lynch syndrome in Western Australia.
    Schofield L; Grieu F; Amanuel B; Carrello A; Spagnolo D; Kiraly C; Pachter N; Goldblatt J; Platell C; Levitt M; Stewart C; Salama P; Ee H; Raftopoulous S; Katris P; Threlfall T; Edkins E; Wallace M; Iacopetta B
    Int J Cancer; 2014 Sep; 135(5):1085-91. PubMed ID: 24474394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lynch syndrome screening in newly diagnosed colorectal cancer in general pathology practice: from the revised Bethesda guidelines to a universal approach.
    Morrison J; Bronner M; Leach BH; Downs-Kelly E; Goldblum JR; Liu X
    Scand J Gastroenterol; 2011 Nov; 46(11):1340-8. PubMed ID: 21879804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.